U.S. markets open in 6 hours 19 minutes

U.S. FDA approves Bristol Myers' combo therapy for lung cancer

May 15 (Reuters) - The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb Co's therapy for previously untreated patients with a form of lung cancer, a much-needed boost as the company battles the dominance of Merck's Keytruda.

The combination of Bristol's treatments, Opdivo and Yervoy, is approved for treating patients with non-small cell lung cancer, the FDA said https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-plus-ipilimumab-first-line-mnsclc-pd-l1-tumor-expression-1. (Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila and Shailesh Kuber)